1521 Stock Overview
Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Frontage Holdings Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.36 |
| 52 Week High | HK$2.58 |
| 52 Week Low | HK$1.32 |
| Beta | 0.81 |
| 1 Month Change | -10.53% |
| 3 Month Change | -34.62% |
| 1 Year Change | -45.60% |
| 3 Year Change | -73.75% |
| 5 Year Change | n/a |
| Change since IPO | -59.40% |
Recent News & Updates
Recent updates
Some Investors May Be Willing To Look Past Frontage Holdings' (HKG:1521) Soft Earnings
Apr 04
What Is Frontage Holdings Corporation's (HKG:1521) Share Price Doing?
Jan 23With Frontage Holdings Corporation (HKG:1521) It Looks Like You'll Get What You Pay For
Dec 29Analysts Just Shaved Their Frontage Holdings Corporation (HKG:1521) Forecasts Dramatically
Sep 03Does Frontage Holdings (HKG:1521) Have A Healthy Balance Sheet?
Apr 11Should You Investigate Frontage Holdings Corporation (HKG:1521) At HK$2.92?
Dec 29Frontage Holdings (HKG:1521) Seems To Use Debt Quite Sensibly
Oct 10Is It Too Late To Consider Buying Frontage Holdings Corporation (HKG:1521)?
Jun 08Is Now The Time To Look At Buying Frontage Holdings Corporation (HKG:1521)?
Jan 04An Intrinsic Calculation For Frontage Holdings Corporation (HKG:1521) Suggests It's 48% Undervalued
Oct 25Here's Why I Think Frontage Holdings (HKG:1521) Might Deserve Your Attention Today
Sep 15Why Frontage Holdings Corporation (HKG:1521) Could Be Worth Watching
Aug 17Is Frontage Holdings Corporation (HKG:1521) Trading At A 26% Discount?
Jul 12Estimating The Intrinsic Value Of Frontage Holdings Corporation (HKG:1521)
Mar 30Frontage Holdings Corporation's (HKG:1521) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Mar 06Don't Ignore The Fact That This Insider Just Sold Some Shares In Frontage Holdings Corporation (HKG:1521)
Feb 03Frontage Holdings (HKG:1521) Shareholders Booked A 46% Gain In The Last Year
Jan 25How Much Of Frontage Holdings Corporation (HKG:1521) Do Institutions Own?
Jan 04A Look At The Intrinsic Value Of Frontage Holdings Corporation (HKG:1521)
Dec 09
Does Frontage Holdings Corporation (HKG:1521) Create Value For Shareholders?
Aug 06Can You Imagine How Frontage Holdings' (HKG:1521) Shareholders Feel About The 34% Share Price Increase?
Jul 22Should You Rely On Frontage Holdings's (HKG:1521) Earnings Growth?
Jul 04Shareholder Returns
| 1521 | HK Life Sciences | HK Market | |
|---|---|---|---|
| 7D | -0.7% | -7.8% | -2.0% |
| 1Y | -45.6% | -69.2% | -14.3% |
Return vs Industry: 1521 exceeded the Hong Kong Life Sciences industry which returned -69.8% over the past year.
Return vs Market: 1521 underperformed the Hong Kong Market which returned -15% over the past year.
Price Volatility
| 1521 volatility | |
|---|---|
| 1521 Average Weekly Movement | 9.3% |
| Life Sciences Industry Average Movement | 10.7% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in HK Market | 14.9% |
| 10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 1521's share price has been volatile over the past 3 months.
Volatility Over Time: 1521's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 1,759 | Abdul Mutlib | www.frontagelab.com |
Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies. It offers laboratory testing services, such as method development and validation, and sample analysis and central laboratory services; chemistry, manufacturing, and control services, including assistance in drug product development and analysis, and delivery and supply of clinical trial materials; and drug metabolism and pharmacokinetic services. The company also provides early stage clinical/bioequivalence services; absolute bioavailability and human radiolabel studies; and chemistry services, including performing custom synthesis.
Frontage Holdings Corporation Fundamentals Summary
| 1521 fundamental statistics | |
|---|---|
| Market cap | HK$2.75b |
| Earnings (TTM) | HK$84.65m |
| Revenue (TTM) | HK$2.04b |
32.5x
P/E Ratio1.4x
P/S RatioIs 1521 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1521 income statement (TTM) | |
|---|---|
| Revenue | US$259.86m |
| Cost of Revenue | US$181.46m |
| Gross Profit | US$78.39m |
| Other Expenses | US$67.59m |
| Earnings | US$10.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0053 |
| Gross Margin | 30.17% |
| Net Profit Margin | 4.16% |
| Debt/Equity Ratio | 23.6% |
How did 1521 perform over the long term?
See historical performance and comparison